Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Kinetin [525-79-1]

Kinetin [525-79-1]

Imprimer Imprimer
Identifiez-vous

Référence HY-N0160-10g

Conditionnement : 10g

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Kinetin (N6-furfuryladenine) belongs to the family of N6-substituted adenine derivatives known as cytokinins, which are plant hormones involved in cell division, differentiation and other physiological processes. Kinetin has anti-aging effects.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Kinetin Chemical Structure

Kinetin Chemical Structure

CAS No. : 525-79-1

This product is a controlled substance and not for sale in your territory.

Based on 5 publication(s) in Google Scholar

Description

Kinetin (N6-furfuryladenine) belongs to the family of N6-substituted adenine derivatives known as cytokinins, which are plant hormones involved in cell division, differentiation and other physiological processes. Kinetin has anti-aging effects[1].

In Vitro

Kinetin (N6-furfuryladenine) shows to have a direct effect on superoxide dismutase activity in plants; prevent oxidation of unsaturated acids in plant membranes; slow down development and aging in insects, by reducing their fecundity and increasing the specific activity of catalase; and delay the onset of many age-related characteristics that appear in normal human skin fibroblasts undergoing aging in vitro. Kinetin (70-150 μM) markedly suppressed hydroxyl radical formation by about 41% and 76%, respectively[1].
The plant cytokinin kinetin dramatically increases exon 20 inclusion in RNA isolated from cultured familial dysautonomia (FD) cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Kinetin Related Antibodies
In Vivo

Kinetin (N6-furfuryladenine) (2-6 mg/kg; injection into the tail vein) effectively prevents ADP-induced acute pulmonary thrombosis in mice[1].
Subjects received 23.5 mg/kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes was noted after 8 d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ADP-induced acute pulmonary thrombosis 20-24 g mice (ICR strain)[1]
Dosage: 2, 4, 6 mg/kg
Administration: Injection into the tail vein
Result: Reduced mortality to 70%, 40% and 35% at 2, 4, and 6 mg/kg, respectively.
Essai clinique
Masse moléculaire

215.21

Formule

C10H9N5O
CAS No.

525-79-1
Appearance

Solid

Color

White to light yellow

SMILES

C12=NC=NC(NCC3=CC=CO3)=C1N=CN2
Structure Classification
  • Others
Initial Source
  • Plants
  • other families
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : 33.33 mg/mL (154.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1M NaOH : 33.33 mg/mL (154.87 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.6466 mL 23.2331 mL 46.4662 mL
5 mM 0.9293 mL 4.6466 mL 9.2932 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (11.62 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (11.62 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
Références

  • [1]. Hsiao G, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol. 2003 Apr 4;465(3):281-7.  [Content Brief]

    [2]. Hims MM, et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl). 2007 Feb;85(2):149-61.  [Content Brief]

    [3]. Axelrod FB, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov;70(5):480-3.  [Content Brief]

    [4]. Griffaut B, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int J Biol Macromol. 2004 Aug;34(4):271-5.  [Content Brief]

  • [1]. Hsiao G, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol. 2003 Apr 4;465(3):281-7.

    [2]. Hims MM, et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl). 2007 Feb;85(2):149-61.

    [3]. Axelrod FB, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov;70(5):480-3.

    [4]. Griffaut B, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int J Biol Macromol. 2004 Aug;34(4):271-5.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / 1M NaOH 1 mM 4.6466 mL 23.2331 mL 46.4662 mL 116.1656 mL
5 mM 0.9293 mL 4.6466 mL 9.2932 mL 23.2331 mL
10 mM 0.4647 mL 2.3233 mL 4.6466 mL 11.6166 mL
15 mM 0.3098 mL 1.5489 mL 3.0977 mL 7.7444 mL
20 mM 0.2323 mL 1.1617 mL 2.3233 mL 5.8083 mL
25 mM 0.1859 mL 0.9293 mL 1.8586 mL 4.6466 mL
30 mM 0.1549 mL 0.7744 mL 1.5489 mL 3.8722 mL
40 mM 0.1162 mL 0.5808 mL 1.1617 mL 2.9041 mL
50 mM 0.0929 mL 0.4647 mL 0.9293 mL 2.3233 mL
60 mM 0.0774 mL 0.3872 mL 0.7744 mL 1.9361 mL
80 mM 0.0581 mL 0.2904 mL 0.5808 mL 1.4521 mL
100 mM 0.0465 mL 0.2323 mL 0.4647 mL 1.1617 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Kinetin Related Classifications

  • Neurological Disease
  • Immunology/Inflammation
  • SOD
Help & FAQs

Keywords:

Kinetin525-79-16-Furfuryladenine N6-FurfuryladenineSODSuperoxide DismutasehormonedivisionacutepulmonarythrombosisoxidationagesuperoxideplantcytokininInhibitorinhibitorinhibit